Dextromethorphan and guaifenesin use need to be monitored diligently in patients with "poor metabolizer" CYP2D6 enzyme levels and people that are sedated. This combination medication provides a big median harmful dose (TD50) to median helpful dose (ED50) ratio (or therapeutic index) in these clients. These items will not overcome or https://rafaelcnxgo.activablog.com/29601363/the-5-second-trick-for-dextromethorphan-dxm-for-sale-in-australia